YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Measuring Utility Weights with VAS, TTO and EQ-5D for Severe Stomach Cancer

VAS(Visual Analogue Scale), TTO(Time Trade-Off), EQ-5D(EuroQol-5 Dimension) 방법을 이용한 중증위암의 효용가중치 측정

  • Kim, Hyun-Jeong (Graduate School of Clinical Pharmacy, Sookmyung Women's University) ;
  • Rhee, Jinn-Ie (Graduate School of Health and Social Pharmacy) ;
  • Lee, Eui-Kyung (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
  • 김현정 (숙명여자대학교 임상약학대학원) ;
  • 이진이 (성균관대학교 보건사회약학과) ;
  • 이의경 (숙명여자대학교 임상약학대학원)
  • Published : 2008.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Stomach cancer shows the highest incidence among cancer patients in Korea and it deteriorates the patients' health-related quality of life considerably. This study measured utility weights of severe stomach cancer symptoms using VAS (Visual Analogue Scale), TTO (Time-trade Off) and EQ-5D (EuroQol-5 Dimension) methods. A survey questionnaire was developed to describe the symptoms of severe stomach cancer comprehensively and concisely using VAS, TTO and EQ-5D. A face-to-face interview was conducted for 21 cancer inpatients in a hospital and 25 non-patients. The mean utility weight is 0.498 for VAS, 0.375 for EQ-5D and 0.300 for TTO. Using VAS or TTO methods, there were no statistically significant differences between patients and non-patients while there was significant difference in EQ-5D. The utility weight with VAS and EQ-5D has shown similar trend - higher score in patient group, male and aged while it has opposite trend with TTO.

Keywords

References

  1. 보건복지부, 2002년 한국암등록사업 연례보고서 (2002)
  2. 통계청, 인구 100,000명당 주요 암 사망률 (2002)
  3. Wu, X., Chen, V. W., Andrews, P. A., Ruiz, B. and Correa, P. : Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control 18(6), 585 (2007) https://doi.org/10.1007/s10552-007-9000-1
  4. 이의경 : 약물치료학 제8장 의약품 경제성평가, 신일상사, 서울 (2006)
  5. Kopec, J. A. and Willison, K. D. : A comparative review of four preference-weighted measures of health-related quality of life. Journal of Clinical Epidemiology 56, 317 (2003) https://doi.org/10.1016/S0895-4356(02)00609-1
  6. Drummond, M. F., O'Brien B. J., Stoddart, G. L. and Torrance, G. W. : Methods for the economic evaluation of health care programmes 2nd ed. (1997)
  7. 박조현 : 위암가이드북, (주)국일미디어, 경기 (2007)
  8. Drummond, M. F., Sculpher, M. J., Torrance, G. W., O'Brien, B. J. and Stoddart, G. L. : Methods for the economic evaluation of health care programmes. 3rd ed. 205 (2005)
  9. Norum, J. and Angelsen, V. : Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens. Journal of Chemotherapy 7(5), 455 (1995) https://doi.org/10.1179/joc.1995.7.5.455
  10. Daly, E., Gray, A., Barlow, D., McPherson, K., Roche, M. and Vessey, M. : Measuring the impact of menopausal symptoms on quality of life. BMJ 307(2), 836 (1993) https://doi.org/10.1136/bmj.307.6908.836
  11. Wildi, S. M., Cox, M. H., Clark, L. L., Tuner, R., Hawes, R. H., Hoffman, B. J. and Wallace, M. B. : Assessment of health state utilities and quality of life in patients with malignant esophageal dysphagia. American Journal of Gastroenterology 1044 (2004)
  12. Milne, R. J., Heaton-Brown, K. H., Hansen, P., Thomas, D., Harvey, V. and Cubitt, A. : Quality-of-life valuations of advanced breast cancer by New Zealand Women. Pharmacoeconomics 24(3), 281 (2006) https://doi.org/10.2165/00019053-200624030-00007